Madrid, Spain and Heidelberg, Germany, December 18, 2013 - SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03, Prime Standard) today announced that the Company successfully placed the remaining shares and ultimately closed the share capital transaction announced on October 2nd, 2013.
CureVac, a German clinical stage biopharmaceutical company, today announced that it has reached the targeted number of patients for its phase IIb clinical trial of the mRNA-based immunotherapy CV9104 in patients with prostate cancer within the anticipated timeline. To date CureVac has included more than 195 chemotherapy-naïve patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer in eight European countries into the study.
Apogenix, a clinical stage biopharmaceutical company, announced today that the data published in the December issue of Molecular Cancer Therapeutics demonstrate effective antitumor activity of the company’s drug candidate APG350, an activator for TRAIL receptors. The publication shows that APG350’s novel molecular structure allows for potent induction of apoptosis of tumor cells independent of the innate immune system, thus overcoming the limitations of other TRAIL receptor agonists.
SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today reported results for the first nine months ended 30 September 2013.
immatics biotechnologies GmbH and Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced a strategic research and development collaboration covering multiple cancer vaccines and immunotherapeutics.
Cosmo Pharmaceuticals, (SIX:COPN), announces today that in connection with the announced merger agreement of November 7, 2013 between Salix Pharmaceuticals, Ltd. and Santarus, Inc., Salix and Santarus entered into an agreement with Cosmo restructuring certain aspects of Santarus’ relationship with Cosmo existing under the license agreement of December 10, 2008.
SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard segment of the German Stock Exchange), the DNA amplification and sequencing company, announced today the attendance at two major German investor conferences in November and December 2013.
WILEX AG (ISIN DE0006614720/ WL6 / FSE) and Prometheus Laboratories Inc. (Prometheus), San Diego, CA, USA, agreed as of 31 October 2013 on the terms of the termination of the 2011 license agreement on RENCAREX® (Girentuximab). As announced on 3 June 2013, Prometheus and WILEX decided to finalise the cooperation and to discuss the formalities and timing regarding the termination.
SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that Molecular Cell, one of the scientific journals in the Molecular Biology field with the highest impact factor, belonging to the same group that publishes “Cell”, has recently published the paper “PrimPol, an Archaic Primase/Polymerase Operating in Human Cells”.
The 1st International mRNA Health Conference in Tübingen on Oct. 23 and 24 brought together for the first time more than 150 attendees from leading international pharmaceutical and biotechnology companies and academic institutions. The attendees discussed in the two-day event the tremendous medical potential of mRNA for many therapeutic indications. The conference, hosted by the University of Tübingen, the University Hospital of Tübingen and CureVac, laid the foundation for the new biotechnological sector of mRNA-based therapeutics.
SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard segment of the German Stock Exchange), the DNA amplification and sequencing company, announced today that GBC Research, a German independent research house focusing on listed small, and midcap companies, has published a research update following the successful completion of the Company’s capital increase as of October 28, 2013.
SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03, Prime Standard) today announced that the Company has successfully completed its rights offering. The subscription price was € 2.65 per share. New shares that were not subscribed in the course of the rights offering by existing shareholders were offered to selected German and international institutional investors in a private placement at a purchase price equivalent to the subscription price. In the transaction 1,019,309 new shares against cash were subscribed.
immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced multi-peptide cancer vaccines that are active against cancer, today announced that it has closed a €34 million Series D financing round.
WILEX AG (ISIN DE0006614720 / WL6 / FSE) today published its financial figures for the first nine months of the 2013 financial year and reported on the progress of its projects.
Cosmo Pharmaceuticals, (SIX:COPN), announces today that the USPTO has issued its patent application under reference US 8,545,811. This patent was filed in 2010.
CureVac, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on Messenger RNA (mRNA), today announced that it has entered into a collaboration and licensing agreement with Janssen Pharmaceuticals, Inc. Under the agreement CureVac will
collaborate with Crucell Holland B.V. (a member of the Janssen Pharmaceutical Companies) on the development of an influenza vaccine based on CureVac’s RNActive® technology.
SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03, Prime Standard) announced that the Management Board of SYGNIS today resolved with the approval of the Supervisory Board to increase the Company’s share capital by up to EUR 1,170,532.00 from EUR 9,364,258.00 to up to EUR 10,534,790.00 by issuing up to 1,170,532 new shares against cash contribution.
Cosmo Pharmaceuticals S.p.A. (SIX:COPN) today announced that it has sold existing treasury shares on behalf of certain employees and directors for CHF 33.8 million through a follow-on offering to institutional investors via an accelerated bookbuilding procedure announced on 19 September 2013. The treasury shares have been sold on behalf on certain employees and directors as a result of their exercise of stock options.
WILEX AG (ISIN DE0006614720/ WL6 / FSE) and Nuclea Biotechnologies, Inc., Pittsfield, MA, USA, (Nuclea) today signed a share deal agreement under which Nuclea acquires all shares of WILEX Inc., Cambridge, MA, USA, (Oncogene Science), a wholly owned US subsidiary of WILEX AG. Under the terms of the deal, Nuclea will assume all the assets of WILEX Inc. and will also assume responsibility for repayment of USD 2.5 million under an intercompany loan between WILEX Inc. and WILEX AG. In addition, WILEX AG is eligible for single-digit royalties on net sales on the HER-2/neu and CAIX assays.
WILEX AG today announced that its subsidiary Heidelberg Pharma GmbH, Ladenburg, Germany, signed a license agreement with Roche covering the development of a novel class of antibody drug conjugates (ADCs) based on Heidelberg Pharma’s patented technology to couple α-Amanitin to antibodies. The license agreement covers initial joint research to apply this technology to multiple Roche antibodies towards the identification of development candidates with favourable efficacy/safety profiles.
At the Annual General Meeting (AGM) of SYGNIS Pharma AG held on 28 August 2013 shareholders representing about 94 percent of the capital approved all proposals of the Management with an overwhelming majority. Main decisions were related to the discharge of the members of the Supervisory and the Management Board for the past Fiscal Year, the election of new members of the Supervisory Board, the change of the trade name of the Company (new trade name will be: SYGNIS AG), as well as the creation of new authorised capital.
SYGNIS Pharma AG today reported results for the first six months ended 30 June 2013.
WILEX AG today announced that the first patients were enrolled and dosed in a clinical phase I trial with the PI3K inhibitor WX-037. The open-label, dose-escalation study is being conducted in patients with solid tumours in three study centres in the UK.
New product sales exceed expectations and important progress is attained in products in development strong increase in profits.
Novaliq GmbH, a drug delivery company with a focus on the topical application of ophthalmic technologies for poorly soluble drugs, today announced the successful CE mark approval for the first topical eye lubricant based on Novaliq’s proprietary technology EyeSolTM.
SYGNIS Pharma AG today reports on the granting of a loan for a total amount of up to EUR 0.55 million by a group of international investors.
WILEX AG published today its financial report for the first six months of the 2013 financial year (1 December 2012 – 31 May 2013). The WILEX Group, comprising WILEX AG and the subsidiaries WILEX Inc. and Heidelberg Pharma GmbH, reports consolidated figures and on three operating segments.
WILEX AG and UCB announced today that UCB has acquired an antibody programme from WILEX’ preclinical portfolio originally obtained from UCB in 2009. UCB has the right to develop the antibodies from the programme in any indication outside the field of oncology, while WILEX keeps the rights to develop for oncology indications.
SYGNIS Pharma AG today reports on the granting of a loan for a total amount of up to EUR 0.55 million by a group of international investors.
Wie Wirbelkanal-Spezialisten heute die Schmerzen nehmen
A highly innovative project supported by a €6 million European Union Framework 7 (EU FP7) program grant to develop a novel class of therapeutic cancer vaccines is now under way.
The Glioma Actively Personalized VAccine Consortium (GAPVAC) is the first EU-funded initiative aimed at clinically developing biomarker-guided actively personalized vaccines (APVACs) to treat cancer patients. The consortium consists of 14 organizations from the biotech industry and academia with cutting-edge expertise in cancer vaccine development. The consortium will be led by immatics biotechnologies GmbH (Coordinator) and BioNTech AG (Vice Coordinator). Both companies are located in Germany and are dedicated to a biomarker-guided approach to fight cancer.
WILEX AG has engaged the investment banking firm Burrill Securities LLC as its exclusive advisor to assist the Company in selecting partners for the financing of WILEX’s projects.
Apogenix GmbH, a clinical stage biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases, announced today that it was able to expand the patent protection for its lead product candidate Apocept™ (APG101). The company was recently granted two patents that cover the medical use of Apocept (APG101) in Europe and Canada.
Cosmo Pharmaceuticals, announced today that the US Food and Drug Administration (FDA) agrees that the design and planned analysis of the study proposed by Cosmo adequately address the objectives necessary to support a regulatory submission for Marketing authorization of the product.
Cosmo Pharmaceuticals, a Specialty Pharmaceutical company based in Milan, Italy has developed a core proprietary drug delivery technology (Multi-Matrix, MMX®) which enables drugs to be efficiently targeted to the colon.
WILEX AG published the results from the Phase III ARISER trial with RENCAREX® for the adjuvant treatment of patients with clear cell renal cell carcinoma at the Annual Meeting of the American Society of Clinical Oncology (ASCO). The data were presented by Professor Arie S. Belldegrun, Principal Investigator of the ARISER trial, Director of the UCLA Institute of Urologic Oncology and Chief of Urologic Oncology at the David Geffen School of Medicine at UCLA, Los Angeles.
As in previous years, joimax® will present a lunch symposium during the 64th Annual Meeting of the German Society of Neurosurgery DGNC to be held in Düsseldorf, Germany, on 27 May 2013. As a world premiere joimax® will introduce its novel EndoLIF® system for endoscopic stabilization of the lumbar spine.
Agennix AG today announced that at the Company's Extraordinary General Meeting (EGM) on Wednesday, May 22, 2013, its shareholders voted in favor of the liquidation of Agennix AG, the public entity.
Spanish-German biotech company SYGNIS Pharma AG has signed a licence agreement for the distribution of a new amplification buffer with QIAGEN, the global leader in sample and assays technologies. This is the second agreement with QIAGEN within 9 months and the first licence agreement for the amplification buffer technology developed by the team led by renowned Professor Margarita Salas at the CSIC laboratory.
SYGNIS Pharma AG today announced its financial results according to IFRS for the first quarter of 2013, ending 31 March 2013.
Cosmo Pharmaceuticals today announced that Shire plc prevailed in its litigation against the Watson Pharmaceuticals Group (now Actavis) in connection with their Abbreviated New Drug Application (“ANDA”) for a generic version of LIALDA®. The Southern District Court of Florida upheld the validity of the patent covering LIALDA® and ruled that the proposed ANDA formulation infringes the claims of the patent and that the FDA is prohibited from approving the ANDA formulation until the patent expires in 2020.
Cosmo Pharmaceuticals, (SIX:COPN) today announced that the underwriter Jefferies LLC exercised its option to purchase an additional 637’500 Santarus (SNTS:NASDAQ) shares at $ 18.25 from its subsidiary Cosmo Technologies Ltd. Thus the entire number of Santarus shares sold by Cosmo increased to 4’887’500 Santarus shares. Santarus did not sell any shares and will not receive any proceeds from the offering.
Cosmo Pharmaceuticals, (SIX:COPN) today announced that its subsidiary Cosmo Technologies Ltd, has placed 4’250’000 of its 7’878’544 Santarus (NASDAQ:SNTS) shares in a secondary underwritten public offering to investors in the USA at $ 18.25 per share. Cosmo Technologies granted Jefferies LLC, the underwriter, an option for thirty days to purchase up to 637’500 additional SNTS shares at the same price. Santarus did not sell any shares and will not receive any proceeds from the offering.
SYGNIS Pharma AG today reported results for the fiscal year 2012 ending on December 31, 2012. The reverse acquisition of X-Pol Biotech led to a change in the fiscal year. Due to the business combination the new SYGNIS includes the total income and expenses of X-Pol for 2012 and those of old SYGNIS only for December 2012, which affects equity in the fully consolidated balance sheet accordingly.
The biotech company SYGNIS Pharma AG has been granted a patent by the USPTO (US patent and Trademark office) for its flagship product, QUALIPHI® the polymerase for complete DNA amplification. Polymerase proteins are the main tool for amplifying long DNA fragments and whole genomes, and are a basic need for research involving the analysis and modification of DNA.
WILEX AG published its financial report for the first three months of the 2013 financial year (1 December 2012 – 28 February 2013) and reported on the status of the Group’s projects.
Novaliq GmbH, a drug delivery company with a focus on the efficacious topical application of poorly soluble drugs, today announced the successful completion of a fifth round of financing of €13.9m ($18.1m). Since 2007, the company has raised €27.1m ($35.2m).
Agennix AG today provided an update regarding strategic options and its activities to further conserve cash.
Cosmo Pharmaceuticals S.p.A. today announced its results for the year ended 31 December 2012.
Company also Postpones Reporting of Fiscal Year 2012 Financial Results and Provides Updated Cash Reach Guidance
SYGNIS Pharma AG today announced that Chief Financial Officer (CFO) and member of the Management Board, Peter Willinger will be stepping down effective 31 March 2013 for personal reasons.
immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announces today that the Company’s scientific inspirer and co-founder Professor Dr Hans-Georg Rammensee has been awarded the Hansen Family Award 2013 for his contribution to the advancement of cancer immunotherapy.
WILEX AG today published its financial results and annual report for the 2012 financial year (1 December 2011 – 30 November 2012).
WILEX AG today announced that the subgroup and biomarker analysis of the Phase III ARISER trial conducted over the last few months has been completed.
Apogenix GmbH, a clinical stage biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases, announced today that its lead product, Apocept™ (APG101), has been granted orphan drug designation from the US Food and Drug Administration (FDA) for the treatment of Myelodysplastic syndromes (MDS).
Das börsennotierte Heidelberger Biotechnologie-Unternehmen SYGNIS Pharma AG hat seine bisherigen Tätigkeiten auf dem Gebiet der Erforschung und Entwicklung von Therapeutika gegen Erkrankungen des Nervensystems beendet. Es fokussiert sich fortan auf die Entwicklung und Vermarktung neuartiger molekularbiologischer Technologien. Zum Beispiel auf den Gebieten der DNA-Amplifikation und -Sequenzierung und des Screenings von Wirkstoffkandidaten.
Cosmo Pharmaceuticals announces that it was informed by the Dutch Regulatory Agency (MEB) that the Appeals Committee put in place to review the MEBs decision of August 8, 2012 has now approved CortimentTM (budesonide with Cosmo’s MMXTM technology), indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis for marketing in the Netherlands.
WILEX AG today announced that its US subsidiary WILEX Inc., Cambridge, MA, USA, entered into a non-exclusive marketing and distribution agreement with Immuno-Biological Laboratories Inc., Minneapolis, MN, USA, (IBL-America) for the commercialization of the complete diagnostic portfolio in the USA.
Cosmo Pharmaceuticals S.p.A. will present to its shareholders, analysts and the financial press a comprehensive update on its clinical pipeline and its commercial implications at its R&D day to be held today at its headquarters in Lainate starting at 11:00 CET.
WILEX AG today announced that its US subsidiary WILEX Inc., Cambridge, MA, has entered into an exclusive distribution agreement with GeneDiagnostics Inc. for the commercialization of the serum HER-2/neu ELISA test in China.
Cosmo Pharmaceuticals, today announced that its licensee in the USA, Santarus announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for UCERISTM (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis. Santarus expects the commercial launch of UCERIS to begin in March 2013.
The biotech company SYGNIS Pharma AG has been granted the European and US patent for a new basic technology for the detection of proteinprotein interactions, a screening platform for the development of novel drugs.